Directions: Use the information in the following paragraph to create a table that can replace the text. Refer to §4.1 of the *AMA Manual of Style*.

Of the 281 patients assigned to the chemoradiotherapy group, 181 (64.4%) completed treatment as planned; however, 100 patients in the chemoradiotherapy group stopped treatment for a variety of reasons. Forty-nine patients (17.4%) stopped treatment because of toxic effects (investigators were not required to indicate the specific toxic effect that prompted the cessation of treatment). Twenty-three (8.2%) declined treatment, 13 (4.6%) had progression of disease while receiving treatment, 3 (1.1%) died during treatment, and 12 (4.3%) discontinued treatment for other reasons.
Directions: Use the information in the following paragraph to create a CONSORT flow diagram to replace the text. Refer to §4.2.2.1 of the *AMA Manual of Style*.

A total of 1326 patients were eligible for inclusion into the study. Of these patients, 78 were excluded from study participation: 26 provided no reason lack of participation, 20 did not meet the inclusion criteria (7 had no health insurance, 6 had cardiac arrest, 4 were younger than 18 years, 2 had contraindications to succinylcholine, and 1 was under guardianship), 12 had physicians who declined them from participating, 11 had improvements in their clinical conditions, and 9 declined to participate. Therefore, 1249 patients were randomized. A total of 624 patients were randomized to the rocuronium group and 624 to the succinylcholine group. In the rocuronium group, 613 received intervention as randomized and 11 did not (5 withdrew consent, 3 had no health insurance, 1 was younger than 18 years, 1 was under guardianship, and 1 was pregnant). In the succinylcholine group, 617 received intervention as randomized and 7 did not (2 were under guardianship, 2 withdrew consent, 2 had no health insurance, and 1 was younger than 18 years). Of the 613 analyzed patients in the rocuronium group, 2 had no intubation attempted and 1 received succinylcholine. Of the 617 analyzed patients in the succinylcholine group, 1 received rocuronium. Therefore, 610 patients in the rocuronium group and 616 in the succinylcholine group were included in the per-protocol analysis.